Previous 10 | Next 10 |
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cass...
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though it...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Summary Most of those who improved while taking Cassava Sciences' drug candidate simufilam had mild cognitive impairment. Most of those who declined while taking simufilam had mild Alzheimer's Disease. Until the FDA decides on simufilam in a couple of years or more, Cassava Sciences...
Summary Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer’s disease. The market reacted negatively anyway. Consequently, investors may 'buy the dip' while waiting for the next trial. On January 24, Cassava Sciences (SAVA), a large ($1.23 bil...
Summary Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly. Cassava Sciences has had two major institutional purchases recently. Introduction I continue to maintain a strong buy rating on...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest decliners in today’s market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today’s trough on the company’s announced mid-stage results...
Cassava Sciences ( NASDAQ: SAVA ) dropped ~17% on Tuesday morning after reporting top-line Phase 2 results for its oral Alzheimer’s candidate simufilam from a study involving patients with mild-to-moderate disease. The open label trial involved more than 200 patients ...
ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less t...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...